What is Noble Financial’s Forecast for TNXP Q1 Earnings?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) – Stock analysts at Noble Financial increased their Q1 2026 earnings per share (EPS) estimates for shares of Tonix Pharmaceuticals in a research note issued to investors on Monday, March 16th. Noble Financial analyst R. Leboyer now forecasts that the company will post earnings per share of ($2.06) for the quarter, up from their previous estimate of ($2.60). The consensus estimate for Tonix Pharmaceuticals’ current full-year earnings is ($1,762.50) per share. Noble Financial also issued estimates for Tonix Pharmaceuticals’ Q2 2026 earnings at ($2.07) EPS, Q3 2026 earnings at ($2.21) EPS, Q4 2026 earnings at ($2.38) EPS and FY2026 earnings at ($8.72) EPS.

Tonix Pharmaceuticals (NASDAQ:TNXP) last announced its quarterly earnings data on Thursday, March 12th. The company reported ($3.98) earnings per share for the quarter, missing the consensus estimate of ($3.16) by ($0.82). Tonix Pharmaceuticals had a negative net margin of 946.22% and a negative return on equity of 60.15%. The firm had revenue of $5.39 million during the quarter, compared to analyst estimates of $2.97 million.

A number of other brokerages also recently weighed in on TNXP. Wall Street Zen raised shares of Tonix Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, January 17th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Tonix Pharmaceuticals in a report on Wednesday, January 21st. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $70.00.

Tonix Pharmaceuticals Stock Down 5.1%

NASDAQ:TNXP opened at $14.19 on Wednesday. The business’s 50-day moving average price is $15.58 and its 200 day moving average price is $18.57. Tonix Pharmaceuticals has a 52-week low of $13.07 and a 52-week high of $69.97. The firm has a market cap of $190.15 million, a P/E ratio of -0.99 and a beta of 1.88.

Insider Activity

In related news, CEO Seth Lederman bought 15,000 shares of the business’s stock in a transaction dated Wednesday, March 18th. The shares were bought at an average cost of $14.89 per share, with a total value of $223,350.00. Following the completion of the transaction, the chief executive officer directly owned 15,001 shares of the company’s stock, valued at approximately $223,364.89. This trade represents a 1,500,000.00% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 0.03% of the stock is owned by company insiders.

Hedge Funds Weigh In On Tonix Pharmaceuticals

Institutional investors have recently bought and sold shares of the stock. Legal & General Group Plc acquired a new stake in Tonix Pharmaceuticals during the 2nd quarter worth about $25,000. Strs Ohio boosted its holdings in shares of Tonix Pharmaceuticals by 9.9% in the fourth quarter. Strs Ohio now owns 7,800 shares of the company’s stock worth $122,000 after buying an additional 700 shares during the period. Ameritas Investment Partners Inc. acquired a new position in shares of Tonix Pharmaceuticals in the second quarter worth about $28,000. Rhumbline Advisers increased its position in shares of Tonix Pharmaceuticals by 8.0% in the third quarter. Rhumbline Advisers now owns 12,206 shares of the company’s stock worth $295,000 after acquiring an additional 908 shares in the last quarter. Finally, Bank of America Corp DE raised its holdings in shares of Tonix Pharmaceuticals by 32.7% during the third quarter. Bank of America Corp DE now owns 4,651 shares of the company’s stock valued at $112,000 after acquiring an additional 1,146 shares during the period. Hedge funds and other institutional investors own 82.26% of the company’s stock.

Tonix Pharmaceuticals News Roundup

Here are the key news stories impacting Tonix Pharmaceuticals this week:

• Positive Sentiment: CEO insider purchase: CEO Seth Lederman bought 15,000 TNXP shares at an average $14.89, increasing his holdings materially — a common bullish signal that management sees value at current levels. Insider Form 4
• Positive Sentiment: Conference visibility: CEO Seth Lederman will present at BIO‑Europe Spring 2026 (Mar 23–25), increasing investor and partner visibility for Tonix’s programs. This can help with business development and raise awareness ahead of clinical readouts. BIO‑Europe Spring 2026
• Positive Sentiment: Scientific exposure: Tonix announced an oral presentation and two poster presentations on its preclinical immuno‑oncology portfolio at AACR 2026 — a potential catalyst if the data generate partner or investor interest. AACR presentations
• Neutral Sentiment: Q4 commentary — mixed fundamentals: Coverage and media pieces note a Q4 revenue beat but an EPS miss, with early signs of momentum for Tonmya (Tonix’s product). Revenue strength is favorable, but continued large losses keep near‑term earnings negative. Seeking Alpha Q4 summary
• Negative Sentiment: Analyst cuts: Noble Financial materially revised 2026 EPS forecasts lower (notably FY2026 to ($8.72) from ($8.01)) and cut several quarterly estimates — a clear negative for sentiment that likely contributed to downward pressure on the share price today.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals is a clinical-stage biotechnology company focused on developing therapeutics for central nervous system disorders, immunology and rare diseases. The company’s pipeline includes small-molecule and biologic product candidates designed to address conditions such as fibromyalgia, post-traumatic stress disorder (PTSD) and other chronic pain syndromes, as well as vaccines for potential viral and biothreat agents.

Among Tonix’s lead programs is TNX-102 SL, a sublingual formulation of cyclobenzaprine being evaluated for the treatment of fibromyalgia and PTSD.